Skip to main content

Advertisement

SpringerLink
Log in

Lung cancer

Defining standard of care for performance status 2—don't rush

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

The standard treatment for patients with advanced-stage non-small-cell lung cancer with a performance status of 2 is unclear because of the heterogeneity of this population. Although a recent trial suggests that carboplatin plus pemetrexed improves survival as compared to single-agent pemetrexed, we should be cautious when defining new standards of treatment on the basis of single small trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gridelli, C. et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann. Oncol. 15, 419–426 (2004).

    Article  CAS  Google Scholar 

  2. Gridelli, C. Treatment of patients with advanced non-small-cell lung cancer with performance status of 2: an unsolved issue. Clin. Lung Cancer 9, 324–325 (2008).

    Article  Google Scholar 

  3. Azzoli, C. G. et al. American Society of Clinical Oncology clinical practice guidelines update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 27, 6251–6266 (2009).

    Article  CAS  Google Scholar 

  4. Peters, S. et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Suppl. 7), vii56–vii64 (2012).

    PubMed  Google Scholar 

  5. Zukin, M. et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.48.1911.

  6. Morabito, A. et al. Randomized phase III trial of gemcitabine and cisplatin vs gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer 81, 77–83 (2013).

    Article  Google Scholar 

  7. Lilenbaum, R. et al. Single-agent versus combination chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J. Thorac. Oncol. 4, 869–874 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, “S. G. Moscati” Hospital, Città Ospedaliera, 8 Contrada Amoretta, Avellino, 83100, Italy

    Cesare Gridelli

Authors
  1. Cesare Gridelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cesare Gridelli.

Ethics declarations

Competing interests

The author has received speaker's honoraria and serves as an advisory board member for the following company: Eli Lilly.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gridelli, C. Defining standard of care for performance status 2—don't rush. Nat Rev Clin Oncol 10, 490–492 (2013). https://doi.org/10.1038/nrclinonc.2013.134

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.134

  • Springer Nature Limited

Search

Navigation